SBIR/STTR Research Award

ASSAY FOR MUTATIONS IN STEM CELLS AND THEIR DERIVATIVES

Award identifier ce5828146e686cf0dfe279b05cfd782e9abec8384676af730e4ae41c29b0d387Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

STTR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INCELL CORPORATION, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
G3XHRGRBCG25
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Stem cell-based therapies hold great promise for the treatment of numerous debilitating diseases and conditions. However, the success of this approach is dependent upon maintenance of genetic integrity in these cells, b oth before and after induction of differentiation to yield specific, functional cell types in vitro, and/or transplantation of differentiated derivatives to mitigate defects in patients in vivo. Currently, the primary method available to assess the genetic integrity of stem cells or their derivatives is karyotyping. This method detects abnormalities in chromosome number or gross defects in chromosomal structure, but does not detect point mutations, including base substitutions, small deletions or small inse rtions, that are responsible for a significant proportion of genetic aberrations leading to abnormal cellular function, including tumorigenesis. This proposal will support the development and validation of a transgene-based assay to determine the frequency and spectrum of point mutations in human and nonhuman primate stem cells and their derivatives. This assay will facilitate a highly relevant assessment of genetic integrity that will provide a critically needed level of quality control and safety assuranc e during the development of a variety of different stem cell-based therapeutic approaches. As the work evolves into Phase II, multiple potential products and tools will be derived from unique non-human primate rhesus and baboon cells and from new and exist ing human cell lines.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

7 SBIR/STTR records share this UEI (1998–2008). Reported award amounts total $1,303,309. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.